CompletedPhase 2/3

Phase 2/3 Study of ALK-001 in Geographic Atrophy

United States200 participantsStarted 2019-05-07

Plain-language summary

This is a double-masked, multicenter, randomized, placebo-controlled clinical trial, evaluating the efficacy and safety of ALK-001 in participants with Geographic Atrophy (GA) secondary to age-related macular degeneration (AMD). Up to 200 participants will receive ALK-001 while up to 100 participants will receive a placebo.

Who can participate

Age range60 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Major Inclusion Criteria: \- At least one eye with geographic atrophy secondary to dry age-related macular degeneration (AMD) Major Exclusion Criteria: \- Medical condition, which may interfere with the progression of GA, prevent performance of study procedures, compliance with protocol, or continuous participation in the study

What they're measuring

Growth Rate of GA Lesions, as Assessed by Fundus Autofluorescence (FAF)

Timeframe: Baseline to 24 months

Trial details

NCT IDNCT03845582

SponsorAlkeus Pharmaceuticals, Inc.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2023-07-25

Results submitted2025-09-30

View on ClinicalTrials.gov More Geographic Atrophy trials